跳至主要内容
临床试验/NCT03570190
NCT03570190已完成不适用

Registry to Evaluate the Impact of a Valve Coordinator on Aortic Stenosis / TAVI Outcome - (German Pilot)

Institut für Pharmakologie und Präventive Medizin3 个研究点 分布在 1 个国家目标入组 161 人开始时间: 2018年12月20日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
161
试验地点
3
主要终点
Adverse event rate

研究概览

简要总结

Prospective, multicenter registry in patients undergoing commercially available balloon expandable valve implantation. The registry will consist of 3 phases:

Prospective determination of baseline Status Quo (3 months):

Documentation of treatment pathways and endpoints of "routine" patients without educational program

Dedicated reflection and training (1 day):

One training session after the observational period to reflect on treatment pathways, exchange between valve coordinators involved, and develop improvements.

Implementation of tailored changes (2 months):

Implementation of the changes developed in the training.

Determination of the effect (3 months):

Coordinator measures optimization changes and determines effects.

详细描述

Along the severe aortic stenosis (sAS) treatment pathway there are delays that may impact quality management and hospital efficiency. A dedicated valve coordinator, interfering with all stages of patient handling throughout the hospital may increase the efficiency of the sAS patient flow, accelerate decision making and clinical outcomes while at the same time decreasing resource consumption.

The hypothesis is that the implementation of a dedicated valve coordinator will improve the patient flow of sAS patients scheduled to undergo TAVI, their outcome, patient and physician satisfaction and will optimize costs.

In total, three centers across Germany (Munich, Düsseldorf, Bad Bevensen) will participate.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • elective patients with a diagnosis of severe symptomatic aortic stenosis and admitted for TAVI

排除标准

  • patients not providing written informed consent

结局指标

主要结局

Adverse event rate

时间窗: 30 days

According to VARC-2 criteria.

Patient satisfaction

时间窗: 30 days

Satisfaction score. The total score range is from 0 (extremely dissatisfied) to 40 (extremley satisfied).

Economic evaluation

时间窗: 12 months

Proportion of early discharges in patients with sAS undergoing TAVI.

Evaluation of differences in length of stay (LoS)

时间窗: 12 months

LoS in days.

次要结局

未报告次要终点

研究者

发起方
Institut für Pharmakologie und Präventive Medizin
申办方类型
Network
责任方
Sponsor

研究点 (3)

Loading locations...

相似试验